Ashwagandha vs Melatonin
Both are commonly discussed for sleep. Ashwagandha and Melatonin both have moderate evidence — Ashwagandha edges ahead on research volume (20 vs 20 studies referenced).
Evidence last reviewed May 2026
Ashwagandha
Adaptogen
Melatonin
Hormone
Evidence
🟡Moderate Evidence
🟡Moderate Evidence
Research says
Research agrees
Research agrees
Expert mentions
356
3 recommend
216
3 recommend
Studies
20
referenced
20
referenced
Study dose
300–600mg
The majority of positive RCTs and the meta-analytic evidence supporting stress and anxiety reduction used standardized extracts (e.g., KSM-66 or Sensoril) in the range of 300–600 mg per day, administered as a single dose or split across two doses; higher withanolide standardization (≥5%) is associated with the studied effects.
0mg
The body's endogenous nightly output is approximately 0.1–0.3 mg; studied supplemental doses range from 0.5 mg (sufficient for phase-shifting per expert consensus) up to 10 mg (common OTC doses), though lower doses of 0.5–1 mg are considered more physiologically appropriate for general sleep onset by clinical experts, as higher doses may blunt receptor sensitivity over time.
Best timing
MorningEveningWith food
EveningEmpty stomach
Who recommends
Caution
Generally safe
Generally safe
Ashwagandha
Key findings
- ·Multiple RCTs and at least one meta-analysis support statistically significant reductions in perceived stress and anxiety with ashwagandha supplementation, making this the best-evidenced use case.
- ·Cortisol reduction has been reported across several placebo-controlled trials, suggesting a plausible biological mechanism underlying the stress-relief effects.
- ·Doses of 300–600 mg per day of standardized extract, consistent with those used in positive clinical trials, are referenced across the reviewed literature as the studied therapeutic range.
Evidence gaps
- ·Long-term safety data beyond 12 weeks is largely absent, leaving the risk profile for extended supplementation — including liver health — poorly characterized.
- ·Most trials use proprietary or specific extract formulations, making it unclear whether findings generalize to the wide variety of ashwagandha products available to consumers.
Melatonin
Key findings
- ·Melatonin is consistently characterized across multiple reviews as a chronobiotic hormone — a darkness signal produced by the pineal gland — not a sedative or sleep drug.
- ·A meta-analysis on dietary supplements found melatonin associated with improvements in sleep quality outcomes, representing one of the stronger evidence-based applications.
- ·A systematic review and meta-analysis supports melatonin use in ICU patients, suggesting potential benefits in this specific clinical population.
Evidence gaps
- ·Long-term safety and efficacy data for melatonin supplementation in healthy adults and children are largely absent from the reviewed literature, leaving many dosing and duration questions unanswered.
- ·Most reviewed studies are narrative reviews or general overviews rather than large, well-controlled RCTs, making it difficult to establish causality or optimal dosing protocols for specific conditions.